Methods for preparing purified polypeptide compositions

Patent metadata

Field	Value
Publication number	US-9394336-B2
Application number	US-201213350644-A
Country	US
Kind code	B2
Filing date	Jan 13, 2012
Priority date	Sep 22, 2008
Publication date	Jul 19, 2016
Grant date	Jul 19, 2016

Abstract

The present invention relates to purified peptidomimetic macrocycles. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications.

First claim

What is claimed is:

1. A pharmaceutically acceptable composition comprising:
a peptidomimetic macrocycle or a pharmaceutically acceptable salt thereof comprising an alpha-helix and a cross-linker connecting a first amino acid and a second amino acid, the cross-linker spanning from 1 turn to 5 turns of the alpha-helix; and
a metal residue, from a metathesis catalyst, at a concentration of from about 0.5 ppm to about 10 ppm by weight as measured by nuclear inductively coupled plasma analysis (ICP) or nuclear inductively coupled plasma mass spectrometry analysis (ICP-ms);
wherein the pharmaceutically acceptable composition is suitable for administration to a human subject,
and wherein the peptidomimetic macrocycle or the pharmaceutically acceptable salt is of Formula (I):

or a pharmaceutically acceptable salt thereof,
wherein:
each A, C, D, and E is independently a natural or non-natural amino acid;
each B is independently a natural or non-natural amino acid,

[—NH-L 3 -CO—], [—NH-L 3 -SO 2 —], or [—NH-L 3 -];
each R 1 and R 2 are independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, each of which except for —H is optionally substituted with halo-;
each R 3 is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, cycloaryl, or heterocycloaryl, each of which except for —H is optionally substituted with R 5 ;
each L is independently a macrocycle-forming linker of the formula -L 1 -L 2 -;
each L 1 , L 2 , and L 3 are independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene, or [—R 4 —K—R 4 —] n , each being optionally substituted with R 5 ;
each R 4 is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene;
each K is independently O, S, SO, SO 2 , CO, CO 2 , or CONR 3 ;
each R 5 is independently halogen, alkyl, —OR 6 , —N(R 6 ) 2 , —SR 6 , —SO 2 R 6 ; —CO 2 R 6 , a fluorescent moiety, a radioisotope, or a therapeutic agent;
each R 6 is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, or a radioisotope;
each R 7 is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, each of which except for —H is optionally substituted with R 5 , or part of a cyclic structure with the D;
each R 8 is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, each of which except for —H is optionally substituted with R 5 , or part of a cyclic structure with the E;
each v and w are independently integers from 1-1000;
u is an integer from 1-10;
each x, y and z are independently integers from 0-10, wherein x+y+z is 2, 3, 4, 5, 6, 7, 8, 9, or 10; and
each n is independently an integer from 1-5.

2. The pharmaceutically acceptable composition of claim 1 , wherein the metal residue comprises ruthenium or osmium.

3. The pharmaceutically acceptable composition according to claim 1 , wherein at least one of the first and second amino acids is an α,α-disubstituted amino acid.

4. The pharmaceutically acceptable composition of claim 3 , wherein the first or second amino acid is α,α-disubstituted.

5. The pharmaceutically acceptable composition of claim 1 , wherein the first amino acid and the second amino acid are separated by three amino acids.

6. The pharmaceutically acceptable composition of claim 5 , wherein the cross-linker comprises from 6 to 14 consecutive bonds.

7. The pharmaceutically acceptable composition of claim 6 , wherein the cross-linker comprises from 8 to 12 consecutive bonds.

8. The pharmaceutically acceptable composition of claim 1 , wherein the first amino acid and the second amino acid are separated by six amino acids.

9. The pharmaceutically acceptable composition of claim 8 , wherein the cross-linker comprises from 8 to 16 consecutive bonds.

10. The pharmaceutically acceptable composition of claim 9 , wherein the cross-linker comprises from 10 to 13 consecutive bonds.

11. The pharmaceutically acceptable composition of claim 1 , wherein the cross-linker spans 1 or 2 turns of the alpha helix.

12. The pharmaceutically acceptable composition of claim 1 , wherein the length of the cross-linker is about 5 Å to about 9 Å per turn of the alpha-helix.

13. The pharmaceutically acceptable composition of claim 1 , wherein the peptidomimetic macrocycle or the pharmaceutically acceptable salt thereof carries a net positive charge at pH 7.4.

14. The pharmaceutically acceptable composition of claim 1 , wherein the concentration of the metal residue is about 0.5 ppm by weight.

15. The pharmaceutically acceptable composition of claim 1 , wherein the concentration of the metal residue is about 1 ppm by weight.

16. The pharmaceutically acceptable composition of claim 1 , wherein the concentration of the metal residue is about 1 to about 5 ppm by weight.

17. The pharmaceutically acceptable composition of claim 1 , wherein the concentration of the metal residue is about 1 to about 10 ppm by weight.

18. The pharmaceutically acceptable composition of claim 1 , wherein the first amino acid and the second amino acid are separated by two amino acids.

19. The pharmaceutically acceptable composition of claim 1 , wherein the concentration of the metal residue is about 0.5 ppm to about 5 ppm by weight.

20. The pharmaceutically acceptable composition of claim 1 , wherein the concentration of the metal residue is about 0.5 ppm to about 1 ppm by weight.

21. A pharmaceutically acceptable composition comprising:
a peptidomimetic macrocycle or a pharmaceutically acceptable salt thereof comprising an alpha-helix and a cross-linker connecting a first amino acid and a second amino acid, the cross-linker spanning from 1 turn to 5 turns of the alpha-helix; and
a metal residue comprising ruthenium, from a metathesis catalyst, at a concentration of below 10 ppm by weight as measured by nuclear inductively coupled plasma analysis (ICP) or nuclear inductively coupled plasma mass spectrometry analysis (ICP-ms);
wherein the pharmaceutically acceptable composition is suitable for administration to a human subject,
and wherein the peptidomimetic macrocycle or the pharmaceutically acceptable salt is of Formula (I):

or a pharmaceutically acceptable salt thereof,
wherein:
each A, C, D, and E is independently a natural or non-natural amino acid;
each B is independently a natural or non-natural amino acid,

[—NH-L 3 -CO—], [—NH-L 3 -SO 2 —], or [—NH-L 3 -];
each R 1 and R 2 are independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, each of which except for —H is optionally substituted with halo-;
each R 3 is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, heteroalk

Assignees

• Nash Huw M
• Iadanza Matthew
• Leitheiser Christopher
• Kawahata Noriyuki
• Aileron Therapeutics Inc

Inventors

• Nash Huw M
• Iadanza Matthew
• Leitheiser Christopher
• Kawahata Noriyuki

Classifications

• A61P5/00

  Drugs for disorders of the endocrine system · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61P7/06

  Antianaemics · CPC title